Prevention of positive coronary artery remodeling with statin therapy in patients with coronary artery diseases

Angiology

Volumn 57, Issue 3, 2006, Pages 259-265

  Suzuki, Makoto ^a   Saito, Makoto ^a   Nagai, Takayuki ^a   Saeki, Hideyuki ^a   Kazatani, Yukio ^a  

^a EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVENTITIA; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ELASTICITY; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RHABDOMYOLYSIS; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; ECHOGRAPHY; MIDDLE AGED; RECURRENT DISEASE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; RECURRENCE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33745566091     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700301     Document Type: Article

References (25)

1. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.
2. The long-term intervention with pravastatin in ischemic disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
3. Flaker GC, Warnica JW, Sacks FM, et al: Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol 34:106-112, 1999.
4. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled study. JAMA 285:1711-1718, 2001.
5. Serrurys PWJC, de Feyter P, Macaya C, et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 287:3215-3222, 2002.
6. Glagov S, Weisenberg E, Zarins CK, et al: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371-1375, 1987.
7. Varnava AM, Mills PG, Davies MJ: Relationship between coronary artery remodeling and plaque vulnerability. Circulation 105:939-943, 2002.
8. Schoenhagen P, Ziada KM, Kapadia SR, et al: Extent and direction of arterial remodeling in stable versus unstable coronary syndromes. An intravascular ultrasound study. Circulation 101:598-603, 2000.
9. Pasterkamp G, Schoneveld AH, van der Wal AC, et al: Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: The remodeling paradox. J Am Coll Cardiol 32:655-662, 1998.
10. Suzuki M, Inaba S, Nagai T, et al: Relation of C-reactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction. Am J Cardiol 91:331-333, 2003.
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
12. Tsunekawa T, Hayashi T, Kano H, et al: Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379, 2001.
13. Walter DH, Fichtlscherer S, Britten MB, et al: Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38:2006-2012, 2001.
14. Ridker PM, Rifai N, Clearfield M, et al: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001.
15. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933-1935, 2001.
16. Plenge JK, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452, 2002.
17. Lefer DJ: Stalins as potent antiinflammatory drugs. Circulation 106:2041-2042, 2002.
18. Mintz GS, Painter JA, Pichard AD, et al: Atherosclerosis in angiographically "normal" coronary artery reference segments: An intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 25:1479-1485, 1995.
19. Rasheed Q, Dhawale PJ, Anderson J, et al: Intracoronary ultrasound-defined plaque composition: Computer-aided plaque characterization and correlation with histological samples obtained during directional coronary atherectomy. Am Heart J 129:631-637, 1995.
20. Hiro T, Leung CY, De Guzman S, et al: Are soft echoes really soft? Intravascular ultrasound assessment of mechanical properties in human atherosclerotic tissue. Am Heart J 133:1-7, 1997.
21. Schartl M, Bocksch W, Koschyk DH, et al: Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104:387-392, 2001.
22. Ambrose JA, Martinez EE: A new paradigm for plaque stabilization. Circulation 105:2000-2004, 2002.
23. Corti R, Farkouh ME, Badimon JJ: The vulnerable plaque and acute coronary syndromes. Am J Med 113:668-680, 2002.
24. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 101:207-213, 2000.
25. Corti R, Fayad ZA, Fuster V, et al: Effects of lipid-lowering by simvastatin on human atherosclerotic lesions. A longitudinal study by high-resolution, non-invasive magnetic resonance imaging. Circulation 104:249-252, 2001.